European Annals of Allergy and Clinical Immunology THE OFFICIAL JOURNAL OF AAITO THE OFFICIAL JOURNAL OF SPAIC HOME PAGE
EDITORS IN CHIEF
L. Cecchi (Italy)
P. Carreiro-Martins (Portugal)

DEPUTY EDITORS
R. Rodrigues Alves (Portugal)
M.B. Bilò (Italy)
 
ASSOCIATE EDITORS
R. Asero (Italy)
M. Branco Ferreira (Portugal)
E. Scala (Italy)
D. Solé (Brasil)
G. Sturm (Austria)

EDITORIAL BOARD
I. Agache (Romania)
I. Annesi Maesano (France)
L. Antonicelli (Italy)
G. Azizi (Iran)
L.M. Borrego (Portugal)
K. Brockow (Germany)
S. Bavbek (Turkey)
E. Cichocka-Jarosz (Poland)
M. Cugno (Italy)
L. Delgado (Portugal)
P. Demoly (France)
G. D'Amato (Italy)
S. Durham (UK)
M. Faber (Belgium)
M. Fernandez-Rivas (Spain)
J. Fonseca (Portugal)
ZS. Gao (China)
G.P. Girolomoni (Italy)
E. Goudouris (Brasil)
A. Grumach (Brasil)
G. Kostantinou (Greece)
F. Levi-Shaffer (Israel)
M. Maurer (Germany)
L. Mayorga (Spain)
C. Micheletto (Italy)
M. Morais de Almeida (Portugal)
G. Moscato (Italy)
A. Musarra (Italy)
C. Nunes (Portugal)
M. Ollert (Lussemburgo)
P. Parronchi (Italy)
G. Passalacqua (Italy)
E. Pedro (Portugal)
A. Perino (Italy)
O. Quercia (Italy)
A. Romano (Italy)
G. Scadding (UK)
A. Todo Bom (Portugal)
A. Tedeschi (Italy)
R. van Ree (Netherland)
D. Villalta (Italy)
S. Voltolini (Italy)

FOUNDERS
F. Bonifazi (Italy)
A. Sabbah (France)
************************* 

Chief Business & Content Officer
Ludovico Baldessin

Editorial Coordinator
Barbara Moret

Publishing Editor
Elisa Grignani
e.grignani@lswr.it
Ph. 0039 (0)2-88184.101

Production Manager
Paolo Ficicchia
p.ficicchia@lswr.it
Ph. 0039 (0)2-88184.222

Sales
Stefano Busconi
dircom@lswr.it
Ph. 0039 (0)2-88184.404

EDRA SpA 
Via G. Spadolini, 7
20141 Milano - Italy
Ph. 0039 (0)2-88184.1
Fax 0039 (0)2-88184.301
www.edraspa.it
Table of Contents »

Omalizumab in severe chronic urticaria: are slow and non-responders different?


R. Asero r.asero@libero.it

Show more: Authors information and Publication history

Doi
10.23822/EurAnnACI.1764-1489.167

Summary
Background.
The response to omalizumab by patients with severe chronic spontaneousurticaria (CSU), may be rapid, slow, or absent. An early response hasbeen associated with an IgE-mediated auto-allergic pathogenic mechanism,whereas little is known about slow and non-responders. Objective. To compareCSU patients responding slowly or non-responding to omalizumab. Methods.Forty-six patients showing a slow (n = 23) or absent (n = 23) response to omalizumabout of a cohort of 170 patients with severe CSU (UAS-7 > 30) werestudied. Several baseline clinical and serological parameters were compared in thetwo groups. Results. Apart from a lower prevalence of atopic diseases (p < 0.05)and a slightly higher prevalence of thyroid autoimmunity in non-responders, thetwo groups were similar in terms of clinical and serological features. The majorityof patients in both groups showed low baseline total IgE levels. Conclusions.Patients with severe CSU showing a slow response or not responding at all toomalizumab show impressive similarities. It is currently not possible to predictwhether patients with severe CSU and low IgE levels will show a slow response orwill not respond to anti-IgE treatment.

Key words

Chronic Urticaria; omalizumab; biomarkers; IgE; thyroid autoimmunity.

Cite this article as:
Asero R. Omalizumab in severe chronic urticaria: are slow and non-responders different? Eur Ann Allergy Clin Immunol 2021;53(6):263-6. doi:10.23822/EurAnnACI.1764-1489.167.

FULL TEXT